摘要
目的 初步探讨奥替溴铵 (斯巴敏 )、匹维溴铵 (得舒特 )、马来酸曲美布汀 (舒丽启能 )和酪酸菌 (米雅BM)治疗肠易激综合征的药物经济学。方法 从中国生物医学文献数据库和学术期刊检索相关文献 ,选择符合标准 (随机、双盲、安慰剂对照 )的临床试验论文 ,提取临床试验数据 ,进行药物经济学评价。结果 服用斯巴敏 40mg ,tid ,2wk药费 71.16元 ;服用得舒特 5 0mg ,tid ,2wk药费 12 0 .12元 ;服用舒丽启能 2 0 0mg ,tid ,2wk药费 110 .46元 ;服用米雅BM 80mg ,tid ,2wk药费 2 82 .2 4元。产生单位效果所需的成本分别为斯巴敏 80 .86;得舒特 14 3.17;舒丽启能 135 .37;米雅BM 35 1.0 4。以斯巴敏治疗成本最低。
Aim To evaluate the economics of otilonium Br (Spasmomen), pinaverium Br (Dicetl), trimebutine maleate (Cerekinon) and clostridium butyricum (Miya-BM) in the treatment of irritable bowel syndrome patients.Methods Research papers were selected according to the criteria of randomized, double-blinded, placebo-controlled clinical trial from CBM-Data and academic journals.The trial data in these papers were extracted and the cost-effectiveness analysis was conducted. Results The regime of Spasmomen 40 mg,tid for 2 wk cost $71.16. The regime of Dicetel 50 mg, tid for 2 wk cost $120.12. The regime of Cerekinon 200mg, tid for 2 wk cost $110 46. The regime of Miya-BM 80 mg, tid for 2 wk cost $282.24.The cost-effectiveness of Spasmomen, Dicetel, Cerekinon and Miya-BM was 80.86, 143.17,135.37 and 351.04 respectively.The cost of Spasmomen getting the same effect was the lowest of above 4 regimes.Conclusion The regime of Spasmomen is the best choice for the treatment of irritable bowel syndrome patients.
出处
《胃肠病学和肝病学杂志》
CAS
2002年第4期349-351,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
奥替溴铵
匹维溴铵
马来酸曲美布汀
酪酸菌
肠易激综合征
药物经济学
治疗
Otilonium Br(Spasmomen) Pinaverium Br(Dicetel) Trimebutine maleate(Cerekinon) Clostridium butyricum (Miya BM) Irritable bowel syndrome Pharmacoeconomics
